Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

267 results about "Antibody level" patented technology

Antibody Test Results. Antibody levels can be determined by analyzing a blood sample. Normal values are as follows: TPO antibody: The measured serum level should be less than 9 IU/mL. Anti-Tg antibody: The measured serum level should be less than 4 IU/mL.

Automatic acquisition and analysis system for laying hen breeding data

The invention relates to the technical field of laying hen breeding, and discloses an automatic acquisition and analysis system for laying hen breeding data. The information acquisition unit is used for collecting physiological parameters, behavior data, environmental parameters and health indexes of laying hens in real time; the disease monitoring unit is used for analyzing the collected data and identifying physiological abnormality and behavior change before the disease occurs; the antibody level monitoring unit is used for evaluating the immune response capability of the laying hens to specific pathogens; the environment adaptability evaluation unit is used for evaluating the adaptability of the laying hens to the extreme environment according to the environment parameter change and the physiological response of the laying hens; the breeding decision support unit is used for integrating all data and analyzing the production performance, disease resistance and environmental adaptability of laying hens; an optimal feeding scheme is recommended, medicine use is reduced, and resource allocation is optimized.
Owner:江西省农业技术推广中心

Conserved neutralizing epitope QT7 of the major glycoprotein GP5 of the North American porcine reproductive and respiratory syndrome virus envelope, nucleic acid molecules, expression vectors, neutralizing antibodies and their applications

ActiveCN118496323Bguaranteed specificityGuaranteed sensitivitySsRNA viruses positive-senseVirus peptidesAgglutinating antibodyTGE VACCINE
The present invention discloses a conserved neutralizing epitope QT7 of the main glycoprotein GP5 of the envelope of North American porcine reproductive and respiratory syndrome virus (PRRSV-2), a nucleic acid molecule, an expression vector, a neutralizing antibody and its application. The present invention inserts the neutralizing epitope QT7 into the Peg pili of Salmonella pullorum, introduces the inert carrier bacteria S9H to obtain a recombinant bacterium, and the surface of the recombinant bacterium can functionally express and display the neutralizing epitope QT7, mixes with the pig-derived immune serum on a glass plate, and determines the positive and negative nature of the reaction by observing whether agglutinated particles visible to the naked eye are produced within 2 minutes. The agglutination test can qualitatively and quantitatively determine the agglutination antibody, and the agglutination antibody level measured by the agglutination test directly mediated by the neutralizing epitope antigen QT7-antibody is strongly positively correlated with the PRRSV-2 neutralizing antibody level tested by the classical cell neutralization test, so that the present invention can be used to detect whether there is anti-PRRSV-2 neutralizing antibody and the neutralizing antibody level in the serum sample, and has potential application prospects in the immune effect of PRRSV-2 vaccine, the evaluation and prevention and control of anti-PRRSV-2 neutralizing antibodies.
Owner:YANGZHOU UNIV

Mouse anti-pelteobagrus fulvidraco IgM monoclonal antibody, hybridoma cell strain and application

The invention belongs to the field of monoclonal antibodies, and particularly relates to a mouse anti-pelteobagrus fulvidraco IgM monoclonal antibody, a hybridoma cell strain secreting the monoclonal antibody and application, a CDR region of a heavy chain variable region of the mouse anti-pelteobagrus fulvidraco IgM monoclonal antibody comprises three sequences shown in SEQ ID NO.1-3, and a CDR region of a light chain variable region of the mouse anti-pelteobagrus fulvidraco IgM monoclonal antibody comprises three sequences shown in SEQ ID NO.4-6; the mouse anti-pelteobagrus fulvidraco IgM monoclonal antibody can be obtained by being secreted by a hybridoma cell strain PFM-1B7C12A1B2 with the preservation number of CCTCC (China Center for Type Culture Collection) NO: C2024234. The mouse anti-pelteobagrus fulvidraco IgM monoclonal antibody provided by the invention can be used for Western blot and ELISA specific detection of IgM in a pelteobagrus fulvidraco secretion form, and can be used for flow cytometry identification of pelteobagrus fulvidraco IgM + B cells. The monoclonal antibody is good in specificity, high in sensitivity and strong in affinity, can be used for structural analysis, immune response level detection and the like of pelteobagrus fulvidraco IgM, and lays a foundation for in-depth study of a pelteobagrus fulvidraco immune system and establishment of a vaccine immune effect evaluation method taking the antibody level as an index.
Owner:HUAZHONG AGRI UNIV +1

Application of citrullinated endolectin-1 polypeptide in preparation of rheumatoid arthritis diagnosis product

The invention discloses application of citrullinated endolectin-1 polypeptide in preparation of rheumatoid arthritis diagnosis products, and belongs to the technical field of rheumatoid arthritis diagnosis. The amino acid sequence of the citrullinated endolectin-1 polypeptide is GD-Cit-WSSQQGSKAVYPE, and the amino acid sequence of the citrullinated endolectin-1 polypeptide is GD- The product is used for detecting the content of the anti-citrullinated endolectin-1 polypeptide antibody in a biological sample of a patient, and the antibody level is remarkably different from that of normal healthy people and other common rheumatism immune disease patients easily confused with rheumatoid arthritis in the body of an RA patient. The kit has good sensitivity for common RA, RA with normal ESR and CRP, and anti-CCP antibody / RF negative RA patients, and has good supplementary diagnostic value for RA diagnosis.
Owner:PEOPLES HOSPITAL PEKING UNIV

Bispecific nano antibody for targeting B cells and application of bispecific nano antibody

The invention belongs to the technical field of biology, and discloses a bispecific nano antibody targeting B cells and application of the bispecific nano antibody. The bispecific nano-antibody comprises at least one nano-antibody for recognizing a target point BCMA and one nano-antibody for recognizing a target point CD20. The nano antibody provided by the invention can be specifically combined with B cells in human blood, especially activated plasma cells, by recognizing BCMA and / or CD20 on the surfaces of the B cells, so that the B cells generating pathological antibodies are removed. The nano antibody provided by the invention has the advantages of smaller molecular weight, strong stability, low cost, easy expression and high expression quantity, and is suitable for large-scale production. The nano antibody is combined with the solid-phase carrier, B cells in blood can be cleared in a targeted mode, the number of the B cells in the blood of a patient can be reduced in a short time, the antibody level can be reduced, therefore, the life quality is improved, complications are reduced, and a new treatment choice is provided for the patient who is ineffective or intolerant to traditional treatment.
Owner:GUANGZHOU KONCEN BIOSCI

Recombinant novel coronavirus Omicron variant RBD trimer antigen, immunogenic composition containing same and application of recombinant novel coronavirus Omicron variant RBD trimer antigen

The invention relates to a novel coronavirus recombinant chimeric antigen, a related product thereof, a preparation method and application of the novel coronavirus recombinant chimeric antigen in preparation of a novel coronavirus vaccine. The recombinant chimeric antigen is a recombinant new coronavirus Omicron variant RBD trimer antigen, various types of vaccines based on the recombinant chimeric antigen can induce strong immune response aiming at various subtype variants (including BA.1, BA.2, BA.5, XBB, EG.5, BA.2. 86, JN.1, KP.2 and the like) of the new coronavirus Omicron, and particularly, compared with a protein vaccine of the recombinant chimeric antigen, the recombinant chimeric antigen can induce strong immune response. The mRNA vaccine based on the recombinant chimeric antigen can induce an organism to generate obviously higher RBD specific binding antibody level and neutralizing antibody level, so that the mRNA vaccine can be used as a candidate of a new generation of new coronavirus vaccines, and has potential clinical application value and prospect.
Owner:INST OF MICROBIOLOGY CHINESE ACAD OF SCI

Assessment and treatment of chronic hepatitis b

Provided herein are methods for administering a hepatitis B virus surface antigen (HBsAg) to subjects with chronic hepatitis B to distinguish between responder subjects who respond to the HBsAg administration with an increase in an HBV antibody levels and non‑responder subjects, and treating chronic hepatitis B in the responder subjects with an HBV therapy. Methods of excluding non-responder subjects from a clinical study are also provided.
Owner:BRII BIOSCIENCES INC

Self-presenting antigen-ligand fusion protein, vaccine containing fusion protein and application of vaccine

The invention discloses a self-presenting antigen-ligand fusion protein, a vaccine containing the fusion protein and application of the self-presenting antigen-ligand fusion protein and the vaccine, and relates to the technical field of vaccines, the antigen-ligand fusion protein comprises a first structural unit and a second structural unit, the first structural unit is a virus antigen, and the second structural unit is a CD91 ligand. The antigen-ligand fusion protein provided by the invention can provide a strong and lasting antibody level for an organism.
Owner:BEIJING REXIU BIOTECHNOLOGY CO LTD

Anti-tumor or anti-virus vaccine with IL-9 as adjuvant

The invention relates to the field of biological medicine, in particular to an anti-tumor or anti-virus vaccine with IL-9 as an adjuvant. The invention provides a medicine and / or vaccine for preventing and treating diseases, the medicine and / or vaccine comprises IL-9 and a specific antigen, and experimental results show that compared with other cytokines, IL-9 can significantly enhance the cell and humoral immune intensity induced by antigens such as viruses and tumors, promote immune memory formation and improve the antibody level in serum; compared with vaccines without IL-9, protein vaccines, DNA vaccines or RNA vaccines containing IL-9 can significantly improve the prevention and treatment effect on viruses or tumors, and have wide application prospects in prevention and treatment of diseases caused by tumors, viruses, pathogenic bacteria and the like.
Owner:NEWISH BIOTECHNOLOGY (WUXI) CO LTD

Newcastle disease M1N strain, modification method and recombinant vaccine preparation method

InactiveCN119020301AHigh proliferation efficiencylow costViral antigen ingredientsDepsipeptidesMaternal antibodyChick embryos
The invention discloses a Newcastle disease M1N strain, a modification method and a recombinant vaccine preparation method, the strain is preserved in China General Microbiological Culture Collection Center on January 19th, 2024, the address of the preservation unit is CGMCC No.45869, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the classification name of the strain is the Newcastle disease strain. Compared with La Sota, the recombinant vaccine strain constructed by the invention has higher proliferation efficiency in chick embryos, the inactivated vaccine of the recombinant vaccine strain has better antigenicity, and the level of excited antibodies is higher; and effective antibody level can be excited in chicken with high-level maternal antibody.
Owner:SHANGHAI VETERINARY RESEARCH INSTITUTE CAAS (CHINESE ANIMAL HEALTH & EPIDEMIOLOGY CENTER SHANGHAI BRANCH)

Antigen fusion protein and application thereof in preparation of live vaccine for preventing infectious bursal disease

The invention discloses an antigen fusion protein and application thereof in preparation of a live vaccine for preventing infectious bursal disease. Specifically disclosed are antigen fusion proteins comprising a VP2 protein, a trimer tag, and a C3d protein. The invention also discloses recombinant Eimeria heap constructed by using the antigen fusion protein and application of the recombinant Eimeria heap in preparation of IBDV live vaccines. The oocyst of the recombinant Eimeria heap can effectively induce humoral immune response aiming at IBDV as a vaccine active ingredient, the level of an induced antibody is obviously higher than that of an insect strain expressed by a single VP2 antigen, viruses can be more effectively neutralized, the immune protection efficacy is improved, the safety is high, and the oocyst has the potential of serving as a live vector genetic engineering vaccine. The IBDV live vaccine can be orally taken through drinking water or feed, vaccination is simple, large-scale immunization of chicken flocks can be achieved, and the IBDV live vaccine is economical and efficient and has a wide prospect of being applied to prevention and control of the IBDV of the chicken flocks.
Owner:CHINA AGRI UNIV

ELISA kit for distinguishing listeria monocytogenes and / or listeria ivanovii infection as well as preparation method and application of ELISA kit for distinguishing listeria monocytogenes and / or listeria ivanovii infection

The invention discloses an indirect ELISA (Enzyme-Linked Immunosorbent Assay) detection kit for distinguishing host infected Listeria monocytogenes and / or Listeria ivanovii. The coating antigens are respectively a recombinant listeria monocytogenes surface protein ActA, a serotype 4h listeria monocytogenes and listeria ivanovii common outer membrane protein SmcL and a listeria ivanovii specific outer membrane protein I-inlH, indirect ELISA methods are respectively established based on the three antigens, the three detection methods are combined to detect the content of the listeria monocytogenes, and the content of the listeria ivanovii can be detected. The levels of the ActA antibody, the SmcL antibody and the I-inlH antibody in a clinical serum sample can be effectively monitored, and the detection on the listeria monocytogenes caused by the listeria monocytogenes and / or the listeria ivanovii is realized. The kit is relatively high in sensitivity, strong in specificity and good in stability, and an effective method is provided for epidemiological investigation and diagnosis of listeria monocytogenes.
Owner:YANGZHOU UNIV

Nanometer antibody targeting B cell CD20 and application thereof

The invention belongs to the technical field of biology, and discloses a nano antibody targeting B cell CD20 and application of the nano antibody. The amino acid sequences of the complementarity determining regions CDR1-CDR3 of the nano antibody are selected from SEQ ID NO.1-9. The nano antibody provided by the invention can be specifically combined with B cells in human blood, so that the B cells generating pathological antibodies are removed. Compared with the traditional antibody, the nano antibody provided by the invention has the advantages of smaller molecular weight, high stability, low cost, easiness in expression and high expression quantity, and is suitable for large-scale production. The nano antibody is combined with the solid-phase carrier, B cells in blood can be cleared in a targeted mode, the number of the B cells in the blood of a patient can be reduced in a short time, the antibody level can be reduced, therefore, the life quality is improved, complications are reduced, and a new treatment choice is provided for the patient who is ineffective or intolerant to traditional treatment.
Owner:GUANGZHOU KONCEN BIOSCI

Solid-phase agglutination detection reagent card and detection method thereof

The invention provides a solid-phase agglutination detection test paper card and a detection method thereof. A reaction area of the solid-phase agglutination detection test paper card comprises a reaction film, the reaction film is coated with captured protein and can enrich to-be-detected antibodies in a to-be-detected sample, and the captured protein is combined with the to-be-detected antibodies and then subjected to agglutination reaction with granular antigens in a detection reagent to form an agglutination compound. And the agglutination compound is intercepted in the reaction film for color development. The granular antigen is a cell carrying a specific antigen or a conjugate formed by coupling the specific antigen and an inert carrier, and the granular antigen can be colored or has a luminescence property in various modes. The solid-phase agglutination detection test paper card provided by the invention has the advantages of simple detection steps, short detection time, high sensitivity, accurate detection result, strong specificity and the like, can be used for detecting various diseases and monitoring antibody level, and also has important significance in the fields of infectious disease prevention and control, medical diagnosis and the like.
Owner:INST OF ANIMAL SCI & VETERINARY TIBET ACADEMY OF AGRI & ANIMAL HUSBANDRY SCI +2

Quantification of immunological status and treatment planning

Methods, devices and systems are provided to analyze the immunologic response of patients at various times before, during and / or after immunomodulating therapy, particularly treatment with specialized pulsed electric field energy. In some embodiments, such methods, devices and systems include a laboratory developed test that utilizes a patient tumor biopsy sample and a series of blood draws to determine whether the locoregional therapy (with or without additional systemic therapies, or systemic therapies-alone) was sufficient to facilitate an increase in tumor-specific antibody production. In some embodiments, the focus is on evaluation of baseline antibody levels, prior to any treatment, and changes in levels of antibodies to given antigens, especially in response to a given therapy treatment. In such embodiments, this antibody testing is performed prior to treatment. The treatment, such as delivery of specialized PEF energy to a target tissue, is then performed and antibody levels are checked at one or more later timepoints to detect changes in the presence of antibodies and therefore response to therapy.
Owner:GALVANIZE THERAPEUTICS INC

Varicella-zoster vaccine composition and use thereof

PCT designated stage expiredWO2025113554A1Viral antigen ingredientsAntiviralsAdjuvantNucleotide
A varicella-zoster vaccine composition and use thereof, belonging to the technical field of biological vaccines. The composition comprises a VZV gE antigen and a CpG ODN adjuvant and further comprises an aluminum adjuvant. The nucleotide sequence of the CpG ODN adjuvant is set forth in SEQ ID NO: 1. The CpG ODN adjuvant with a specific nucleotide sequence has better immunostimulatory activity. The provided varicella-zoster vaccine composition can generate a higher humoral immune response earlier and induce protective immunity in advance for at least one month. One immunization can reach or be close to the antibody level of two immunizations of the Shingrix vaccine. Moreover, the longer-time stable high-humoral immunity level can be kept, and cellular immunity can also be generated.
Owner:HUAPU SHIJIAZHUANG PHARMACEUTICAL CO LTD

Varicella zoster vaccine composition and application thereof

The invention discloses a varicella zoster vaccine composition and application thereof, and belongs to the technical field of biological vaccines, the composition comprises a VZV gE antigen, a CpG ODN adjuvant and an aluminum adjuvant, and the nucleotide sequence of the CpG ODN adjuvant is shown as SEQ ID NO: 1. According to the invention, the CpG ODN adjuvant with a specific nucleotide sequence is selected, so that the immunostimulatory activity is better; the varicella zoster vaccine composition provided by the invention can generate high humoral immune response earlier, and induces protective immunity for at least one month in advance; the antibody level of twice immunization of a Shigrix vaccine can be reached or close to once immunization, the stable high humoral immune level for a long time can be kept, and meanwhile cellular immunity can be generated.
Owner:HUAPU SHIJIAZHUANG PHARMACEUTICAL CO LTD

Polypeptide and kit for distinguishing bovine and sheep brucella natural infection and vaccine immune antibody

PendingCN121517517ADepsipeptidesBiological testingBrucella abortusImmunity
The invention relates to the field of immunology, and discloses a polypeptide and a kit for distinguishing bovine and sheep brucella natural infection from a vaccine immune antibody. Polypeptides as shown in SEQ ID NO: 1 and SEQ ID NO: 2 are artificially synthesized and used as antigens to coat an elisa plate and a nitrocellulose membrane, and according to response characteristics of antibody level, identification and detection of natural infection and vaccine immunity of cattle and sheep populations are realized. The peptide fragment and the detection kit provided by the invention can make up the blank of identifying bovine and sheep brucella natural infection and immune antibodies. The method solves the problem that the antibody induced by the attenuated live vaccine and the naturally infected antibody are difficult to distinguish, provides a scientific basis for quarantine and purification of Brucella, and provides a technical guarantee for preventing human diseases and animals, advancing the mouth and protecting the body health of people.
Owner:CHINA AGRI UNIV

Solid-phase agglutination detection test paper card directly marked by antigen and detection method of solid-phase agglutination detection test paper card

PendingCN120908434ABiological testingInfectious DisorderParticulate antigen
The invention provides a solid-phase agglutination detection test paper card directly marked by antigens and a detection method thereof. A reaction area of the solid-phase agglutination detection test paper card comprises a reaction film, the reaction film is coated with captured protein and can enrich to-be-detected antibodies in a to-be-detected sample, and the captured protein is combined with the to-be-detected antibodies and then subjected to agglutination reaction with granular antigens in a detection reagent to form an agglutination compound. And the agglutination compound is intercepted in the reaction film for color development. The granular antigen is a conjugate formed by coupling a specific antigen and an inert carrier, the specific antigen is not a protein, and the specific antigen is specifically combined with an antibody to be detected. The solid-phase agglutination detection test paper card provided by the invention has the advantages of simple detection steps, short detection time, high sensitivity, accurate detection result, strong specificity and the like, can be used for detecting various diseases and monitoring antibody level, and also has important significance in the fields of infectious disease prevention and control, medical diagnosis and the like.
Owner:INST OF ANIMAL SCI & VETERINARY TIBET ACADEMY OF AGRI & ANIMAL HUSBANDRY SCI +2

Rabies virus inactivated vaccine and preparation method thereof

The invention provides a rabies virus inactivated vaccine and a preparation method thereof, and belongs to the technical field of biological medicines. The invention provides a rabies virus inactivated vaccine. The rabies virus inactivated vaccine comprises an adjuvant and an inactivated VSV-rabies recombinant virus, the inactivated VSV-rabies recombinant virus is obtained by carrying out inactivation on a VSV-rabies recombinant live virus; the VSV-rabies recombinant live virus is prepared by replacing envelope protein G of vesicular stomatitis virus with G protein of rabies virus. The inactivated rabies virus vaccine is good in safety and high in induced antibody level, the immune effect of the inactivated rabies virus vaccine is equivalent to that of a live virus vector vaccine, and the inactivated rabies virus vaccine has a certain application value in the aspect of preventing and controlling rabies.
Owner:ZHEJIAN DIFFERENCE BIOLOGICAL TECH CO LTD +1

PDCoV virus mRNA (messenger Ribonucleic Acid) vaccine capable of self-cutting and expressing multiple virus structural proteins and preparation method of PDCoV virus mRNA vaccine

The invention provides a PDCoV virus mRNA (messenger Ribonucleic Acid) vaccine capable of self-cleaving and expressing a plurality of virus structural proteins and a preparation method of the PDCoV virus mRNA vaccine, and the vaccine comprises mRNA for expressing S, M and N proteins of a PDCoV virus and LNP for encapsulating the mRNA, and the LNP is marked as SMN-mRNA-LNP. The invention provides a PDCoV mRNA vaccine strategy based on combination of S, M and N for the first time, the S, M and N structural proteins of the PDCoV are connected by using a self-cleavage peptide P2A, the S protein is subjected to double proline mutation, so that a single mRNA can express multiple PDCoV antigens, and a multi-level defense system is constructed by using the neutralizing antibody induction capability of the S protein, the immune regulation function of the M protein and the cellular immune activation characteristic of the N protein. Through evaluation of immunogenicity, antibody level and challenge protection effect of the vaccine in mice, suckling piglets and pregnant sows, a new idea is provided for development of broad-spectrum and efficient PDCoV vaccines, and a practical basis is provided for research and development of coronavirus multi-antigen mRNA vaccines.
Owner:LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES(LANZHOU BRANCH CENTER OF CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER)

High-affinity mouse anti-snakehead IgM monoclonal antibody, hybridoma cell strain and application

The invention belongs to the technical field of monoclonal antibodies, and particularly relates to a mouse anti-snakehead IgM monoclonal antibody, a hybridoma cell strain and application, a CDR region of a heavy chain variable region of the mouse anti-snakehead IgM monoclonal antibody comprises three sequences as shown in SEQ ID NO.1-3, and a CDR region of a light chain variable region of the mouse anti-snakehead IgM monoclonal antibody comprises three sequences as shown in SEQ ID NO.6-6; the hybridoma cell strain is secreted by a hybridoma cell strain with the preservation number of CCTCC NO: C2023234. The mouse anti-channa argus IgM monoclonal antibody provided by the invention can be used for Western blot and ELISA specific detection of IgM in a channa argus secretion form, and can be used for flow cytometry identification of channa argus IgM + B cells. The monoclonal antibody is good in specificity, high in sensitivity and strong in affinity, and lays a foundation for deep research of a snakehead immune system and establishment of a vaccine immune effect evaluation method taking the antibody level as an index.
Owner:HUAZHONG AGRI UNIV +1

Kit for detecting plasma cell and related antibody level in thymus microenvironment and application

The invention relates to a kit for detecting plasma cells and related antibody levels in a thymus microenvironment and application of the kit. The kit comprises a quantum dot labeled antibody CD138, a quantum dot labeled antibody CD21, a quantum dot labeled AchR, Musk and / or LRP4 receptor, an antigen repair solution and a DNA fluorescent dye solution, wherein the quantum dot labeled antibody CD138, the quantum dot labeled antibody CD21, the quantum dot labeled AchR, the quantum dot labeled Musk and / or the quantum dot labeled LRP4 receptor, the antigen repair solution and the DNA fluorescent dye solution; through the kit, one or more of plasma cells, follicular DC and related antibodies in a thymus (tumor) sample can be detected, so that the immune level of a tissue slice sample is obtained. A method of carrying the antibody by using the quantum dots is adopted, so that a secondary antibody dyeing link in the existing multicolor immunofluorescence technology is omitted, and the efficiency is improved; the quantum dots are used for replacing fluorescent dye, direct marking of tissue slices can be achieved, local positioning of plasma cells and follicular DCs in the thymoma tumor microenvironment is achieved, and both quantity detection and position detection can be achieved.
Owner:TIANJIN MEDICAL UNIV GENERAL HOSPITAL AIRPORT HOSPITAL

A self-cleavable and multiple viral structural protein expressing PDCoV viral mRNA vaccine and a preparation method thereof

The application provides a PDCoV virus mRNA vaccine which can be self-cleaved and expresses multiple virus structure proteins and a preparation method thereof, the vaccine comprises mRNA for expressing PDCoV virus S, M and N proteins, and LNP for encapsulating the mRNA, denoted as SMN-mRNA-LNP. The application firstly proposes a PDCoV mRNA vaccine strategy based on S, M and N combination, connects three structure proteins of PDCoV S, M and N by using a self-cleaving peptide P2A, mutates the S protein with double proline, enables a single mRNA to express multiple PDCoV antigens, and utilizes the neutralizing antibody induction ability of the S protein, the immune regulation function of the M protein and the cell immune activation characteristics of the N protein to construct a multi-level defense system. Through evaluation of immunogenicity, antibody level and challenge protection effect of the vaccine in mice, suckling piglets and pregnant sows, a new idea for developing a broad-spectrum and high-efficiency PDCoV vaccine is provided, and practical basis for research and development of a coronavirus multi-antigen mRNA vaccine is provided.
Owner:LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES(LANZHOU BRANCH CENTER OF CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER)

Application of PHF20 in preparation of medicine for treating systemic lupus erythematosus, method and medicine

The invention belongs to the technical field of biological medicines, and particularly relates to application and a method of PHF20 in preparation of a medicine for treating systemic lupus erythematosus and the medicine. The invention discloses an application of PHF20 in treatment of systemic lupus erythematosus, a lentivirus with murine PHF20 is selected as a gene therapy tool, an R848 induced lupus mouse model is taken as an experimental subject for gene therapy, and results show that injection of the overexpressed PHF20 lentivirus in a lupus mouse body has the following effects: (1) spleen swelling is improved, and spleen index is significantly reduced; (2) reducing urine protein, urea nitrogen level, anti-dsDNA antibody level and IgG antibody level of the model mouse; and (3) the pathological damage to the kidney of the model mouse is relieved. The research results show that the PHF20 serving as the target provides important reference value for potential application prospects in systemic lupus erythematosus gene therapy and even autoimmune disease gene therapy.
Owner:NANJING DRUM TOWER HOSPITAL

Newcastle disease DNA vaccine nano composite adjuvant as well as preparation method and application thereof

The invention relates to the technical field of vaccine adjuvants, in particular to a Newcastle disease DNA vaccine nano-composite adjuvant and a preparation method and application thereof.The composite adjuvant comprises an agent A and an agent B. The agent A is an aluminum-magnesium hydrotalcite nano-particle solution, the agent B is an okra polysaccharide RPS-1 solution, and the agent A is prepared by taking magnesium chloride hexahydrate and aluminum chloride hexahydrate as raw materials through a one-step method. The agent B is prepared by taking fresh okra fruits as raw materials and adopting a water extraction and alcohol precipitation method; the composite adjuvant is used as a loading agent to be matched with a Newcastle disease nucleic acid vaccine for preventing and treating Newcastle disease. According to the present invention, the aluminum-magnesium hydrotalcite and the okra polysaccharide RPS-1 are combined in the composite form, such that the antibody level and the thymus index of the chicken can be improved, and the product can be adopted as the immunopotentiator of the Newcastle disease DNA vaccine, can be adopted as the carrier to protect the DNA vaccine from degradation, can increase the immunocompetence of the DNA vaccine, and can enhance the animal immune function; the method has a certain popularization value in prevention and control of animal infectious diseases.
Owner:HAINAN UNIV

Hydroxychloroquine as a pretreatment to enhance AAV delivery of broadly neutralizing monoclonal antibodies

PCT designated stageWO2026102264A2Organic active ingredientsFermentationTolerance inductionAntiendomysial antibodies
AAV vectors are ideally suited for long-term delivery of a combination of broadly neutralizing antibodies to achieve sterilizing immunity to HIV. Unfortunately, host immune responses to the delivered antibody have severely limited the efficacy. The TLR9 pathway has been identified in initiating adaptive immune responses against AAV and delivered bNAbs. To enhance this strategy, we validated Hydroxychloroquine, a known drug inhibitor of the TLR9 pathway, as a pretreatment to AAV delivery to avoid anti-drug antibody responses. TLR9 signaling inhibition was validated using a HEK-Blue hTLR9 reporter cell line and CpG stimulation. Hydroxychloroquine was also validated in a 3-macaque trial where AAV9-3BNC117 and AAV9-10-1074 were administered along with 3 doses of hydroxychloroquine once a week starting 1 week before AAV inoculation. Unlike historical controls, where 3BNC117 and 10-1074 expression is lost within the first 4-5 weeks, 2 macaques maintained 10-1074 expression and 1 macaque maintained 3BNC117 for the duration of the trial. Anti-3BNC117 antibodies were only observed in 2 of the 3 macaques and were significantly delayed. Anti-10-1074 antibody responses were a log lower than typically observed in historic controls. The use of hydroxychloroquine as a pretreatment for AAV inoculation is a promising strategy. The significant decrease in anti-10-1074 antibody levels and the successful delivery of 10-1074 in 2 macaques and 3BNC117 in 1 macaque was very encouraging. Extending the dosage of hydroxychloroquine beyond 3 doses may be sufficient to observe long-term bNAb expression in all animals and further decrease ADA responses. Together, these data suggest that the short-term treatment of hydroxychloroquine at the time of AAV inoculation has a meaningful impact on tolerance induction to our AAV-delivered bNAbs.
Owner:UNIV OF MIAMI

A traditional Chinese medicine composition for treating thyroiditis, nodular goiter and thyroid nodule, and a preparation method and application thereof

PendingCN122272732AAntiendomysial antibodiesAutoimmune responses
This invention relates to the field of traditional Chinese medicine and natural medicines, and discloses a traditional Chinese medicine composition for treating thyroiditis, nodular goiter, and thyroid nodules, as well as its preparation method and application. The traditional Chinese medicine composition is made from raw materials in parts by weight of 1-30 parts of Prunella vulgaris, 1-30 parts of Taraxacum mongolicum, 1-30 parts of Hordeum vulgare malt, 1-20 parts of Citrus reticulata peel, 1-24 parts of Crataegus pinnatifida, and 1-24 parts of Raphanus sativus seed. It can not only significantly reduce serum TgAb and TPOAb antibody levels, inhibiting the attack of autoimmune response on the thyroid gland from the source, but also effectively reduce lymphocyte infiltration, repair damaged thyroid follicular structure and restore colloid content, thereby reversing immune damage and tissue destruction of the thyroid gland, reducing thyroid nodules, and solving the problems of existing treatments for thyroiditis, nodular goiter, and thyroid nodules that cannot reverse immune damage to the thyroid gland, destruction of follicular structure, and tissue fibrosis.
Owner:GUANGDONG PHARMA UNIV

A method for preparing a tetravalent influenza virus split vaccine

The application discloses a preparation method of a tetravalent influenza virus split vaccine and belongs to the technical field of vaccines. The preparation method of the tetravalent influenza virus split vaccine comprises the following steps: pre-incubation of a chicken embryo, pre-embryo inspection, virus inoculation and culture, post-embryo inspection, cold embryo, virus harvesting, ultrafiltration clarification, zone centrifugation, desugaring, chromatography, virus splitting, virus inactivation, ultrafiltration liquid replacement, sterilization filtration and preparation of a tetravalent influenza virus split vaccine product. Compared with the prior art, the technical means adopted in the application effectively reduces the content of free formaldehyde and improves the antibody level of the vaccine.
Owner:JIANGSU WALVAX BIOTECHNOLOGY CO LTD

A specific epitope polypeptide and its kit and application

The present invention belongs to the field of biomedicine technology, and discloses a specific epitope polypeptide, a kit and an application thereof. The present invention provides a SARS-CoV-2 specific epitope polypeptide associated with neutralizing activity, and its amino acid sequence is shown in SEQ ID No.2. The present invention designs and constructs a SARS-CoV-2 polypeptide microarray, analyzes the IgG and IgM antibody responses induced by the SARS-CoV-2 inactivated vaccine, screens out a series of immune epitope polypeptides associated with the neutralizing activity of antibodies, and establishes a polypeptide indirect ELISA detection kit on this basis. The method has high sensitivity, good specificity, good repeatability and stability, and does not require a high-level biosafety laboratory. It is easy to operate, objective in judging the results, and can achieve the purpose of quickly evaluating the level of new crown vaccine antibodies, providing new means and directions for new crown antibody detection methods.
Owner:SUN YAT SEN UNIV +1